Brokerages Anticipate BioLineRx Ltd. (NASDAQ:BLRX) Will Announce Earnings of -$0.15 Per Share

Wall Street analysts forecast that BioLineRx Ltd. (NASDAQ:BLRXGet Rating) will post earnings of ($0.15) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for BioLineRx’s earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.14). BioLineRx posted earnings of ($0.27) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 44.4%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that BioLineRx will report full-year earnings of ($0.56) per share for the current year, with EPS estimates ranging from ($0.70) to ($0.45). For the next financial year, analysts expect that the business will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.70) to ($0.30). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover BioLineRx.

BioLineRx (NASDAQ:BLRXGet Rating) last posted its quarterly earnings data on Wednesday, March 16th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.06.

Separately, StockNews.com raised shares of BioLineRx from a “sell” rating to a “hold” rating in a report on Thursday.

Shares of BLRX opened at $1.54 on Friday. The business has a 50-day moving average of $1.62 and a 200 day moving average of $2.13. BioLineRx has a fifty-two week low of $1.34 and a fifty-two week high of $6.34.

Several hedge funds have recently added to or reduced their stakes in BLRX. Marshall Wace LLP purchased a new position in shares of BioLineRx during the 4th quarter worth $29,000. Advisor Group Holdings Inc. lifted its position in shares of BioLineRx by 105.9% in the fourth quarter. Advisor Group Holdings Inc. now owns 15,253 shares of the biotechnology company’s stock worth $31,000 after buying an additional 7,844 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in BioLineRx during the third quarter valued at $33,000. Millennium Management LLC bought a new stake in shares of BioLineRx in the 2nd quarter valued at approximately $42,000. Finally, Geneos Wealth Management Inc. boosted its stake in BioLineRx by 63.1% during the fourth quarter. Geneos Wealth Management Inc. now owns 28,950 shares of the biotechnology company’s stock worth $59,000 after buying an additional 11,200 shares during the period. Hedge funds and other institutional investors own 5.46% of the company’s stock.

BioLineRx Company Profile (Get Rating)

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

Read More

Get a free copy of the Zacks research report on BioLineRx (BLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.